3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
9
Pancreatic Neoplasms
7
Glioblastoma
7
Carcinoma, Non-Small-Cell Lung
5
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Lung Neoplasms
3
Colonic Neoplasms
3
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Osteosarcoma
2
Myelodysplastic Syndromes
2
Lymphoma, Follicular
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Acute
2
Glioma
2
Fibrolamellar hepatocellular carcinoma
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urologic Neoplasms
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
pembrolizumab
28
Cisplatin
24
Oxaliplatin
22
Irinotecan
22
Fluorouracil
22
Capecitabine
20
Leucovorin
17
Paclitaxel
16
Cyclophosphamide
14
Trastuzumab
12
Nivolumab
11
Carboplatin
11
Gemcitabine
10
Bevacizumab
10
Docetaxel
9
fludarabine
8
aldesleukin
8
S 1 (combination)
8
Ramucirumab
7
130-nm albumin-bound paclitaxel
7
atezolizumab
6
Albumin-Bound Paclitaxel
6
Taxes
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Biopsy
5
veliparib
4
tislelizumab
4
spartalizumab
4
dehydroftorafur
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Stomach Neoplasms
×
poly ICLC
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled